It’s Halloween, so pardon the bad pun. Acadia Pharmaceuticals (ACAD) is using black magic to dress up a failed depression drug clinical trial into something that resembles a positive result. Don’t be frightened, it’s all make-believe.

I’ll try to keep an explanation as simple as possible. Acadia conducted a Phase 2 clinical trial of its drug pimavanserin in patients with treatment-resistant depression. The study relied on what is known as a sequential parallel comparison design (SPCD) meant to counteract the large placebo effect often seen in depression drug studies. This kind of study is done in two stages, each lasting five weeks.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • the company stated that “weighted average results of Stage 1 and Stage 2” was the study’s “primary endpoint”. so how is it possible that the study was able to be approved and designed using SPCD as an operationalization method and “weighted average results of Stage 1 and Stage 2” as a primary endpoint?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy